Sfoglia per AUTORE
TUCCI M
Collezione ASL Asti

  

Items : 44

Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2025 Feb;23(1):102255. doi: 10.1016/j.clgc.2024.102255. Epub 2024 Nov 1.
2025
ASL Asti
AOU San Luigi di Orbassano

Cinieri S; Di Maio M; Tucci M; De Giorgi U; Russo A; Caffo O; Di Stefano RF; Turco F; Poletto S; Calabrese M; Saporita I; Buttigliero C;

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2024 Sep;27(3):385-392. doi: 10.1038/s41391-023-00775-y. Epub 2023 De
2024
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Cathomas R; Tombal B; Smith MR; Fizazi K; Treglia G; Turco F; Gillessen S; Di Maio M; Vogl UM; Tucci M; Buttigliero C; Di Maio M; Cathomas R; Tombal B; Smith MR; Fizazi K; Treglia G; Gillessen S; Turco F; Tucci M; Vogl UM;

Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Oct;22(5):102138. doi: 10.1016/j.clgc.2024.102138. Epub 2024 Jun 12.
2024
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tucci M; Scagliotti GV; Di Maio M; Palesandro E; Poletto S; Calabrese M; Saporita I; Crespi V; Di Stefano RF; Farinea G; Fossati N; Gallina A; Zilli T; Vogl UM; Buttigliero C; Delcuratolo MD; Gillessen S; Turco F;

Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2024 Mar 1;32(3):202. doi: 10.1007/s00520-024-08392-8.
2024
ASL Asti
AOU Alessandria
AO Ordine Mauriziano

Cinieri S; Rossetti G; Airoldi M; Rossi M; Lanzetta G; Cavanna L; Ibrahim T; Bossi P; Santini D; Tucci M; De Giorgi U; Valsecchi AA; Comandone A; Di Maio M; Fusco V;

2024
ASL Asti

Tucci M; Mandarà M; Giuliani J; Durante E; Buttigliero C; Turco F; Palesandro E; Campisi I; Singh N; Muraro M; Munoz F; Fiorica F;

Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey. in Tumori / Tumori. 2024 Jun;110(3):174-185. doi: 10.1177/03008916241236279. Epub 2024 Mar 10.
2024
ASL Asti
AOU Alessandria
AO Ordine Mauriziano

Vignani F; Cinieri S; Dionisio R; De Giorgi U; Tucci M; Di Maio M; Santini D; Fusco V; Valsecchi AA;

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies. in ESMO open / ESMO Open. 2024 Jul;9(7):103484. doi: 10.1016/j.esmoop.2024.103484. Epub 2024 Jun 19.
2024
ASL Cuneo 2
ASL Asti
AOU Alessandria
AOU Città della Salute di Torino

Santini D; Bertoldo F; Tucci M; Berruti A; Pantano F; Procopio G; Di Maio M; Valsecchi AA; De Giorgi U; Cursano MC;

2024
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Carfì FM; Calabrese M; Saporita I; Pisano C; Delcuratolo MD; Turco F; Di Stefano RF; Samuelly A; Buttigliero C;

TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. in Pathologica / Pathologica. 2024 Feb;116(1):55-61. doi: 10.32074/1591-951X-937.
2024
ASL Asti

Brunelli M; Gobbo S; Malpeli G; Sirgiovanni G; Caserta C; Munari E; Francesconi S; Caliò A; Martignoni G; Cimadamore A; Veccia A; Antonelli A; Tucci M; Pierconti F; Hattab IM; Eccher A; Ascani S; Milella M; Buffoni L; Cheng L; Bracarda S;

2024
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Di Stefano FR; Audisio M; Turco F; Delcuratolo MD; Poletto S; Saporita I; Carfì F; Calabrese M; Farinea G; Buttigliero C;

TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7.
2024
ASL Cuneo 2
ASL Asti
ASL Città di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Buttigliero C; Vellani G; Rossi M; Gennari A; Maio MD; Tucci M; Ortega C; Airoldi M; Numico G; Depetris I; Comandone A; Vormola R; Buosi R; Stevani I; Guglielmini P; Icardi M; Dionisio R; Vignani F; Cattrini C; Mennitto A; Prati V; Pisano C; Turco F; Arnaudo E; Fea E; Vanella P; Vana F; Brusa F; Filippi R; et alii...

How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists. in Cancer treatment reviews / Cancer Treat Rev. 2024 Apr;125:102692. doi: 10.1016/j.ctrv.2024.102692. Epub 2024 Jan 23.
2024
ASL Asti

Tucci M; Cosmai L; Pirovano M; Campisi I; Re SGV; Porta C; Gallieni M; Piergiorgio M;

Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2023 Jan;181:103881. doi: 10.1016/j.critrevonc.2022.103881. Epub 2022 Nov 24
2023
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Scagliotti GV; Di Maio M; Brusa F; Audisio A; Di Stefano RF; Ungaro A; Audisio M; Samuelly A; Turco F; Tucci M; Delcuratolo MD;

Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer. in International journal of molecular sciences / Int J Mol Sci. 2023 Dec 20;25(1):78. doi: 10.3390/ijms25010078.
2023
ASL Asti
AOU San Luigi di Orbassano

Farinea G; Poletto S; Carfì FM; Di Stefano RF; Vogl UM; Castro E; Gillessen S; Turco F; Saporita I; Calabrese M; Tucci M; Buttigliero C;

2023
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Scagliotti GV; Di Maio M; Parlagreco E; Ungaro A; Audisio M; Audisio A; Samuelly A; Pisano C; Urban S; Tucci M; Angusti T; Parente A; Di Stefano RF; Turco F; Turco F; Tucci M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Audisio A; Audisio M; Parlagreco E; Ungaro A; Scagliotti GV; Di Maio M; et alii...

How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy? in Research and reports in urology / Res Rep Urol. 2023 Jan 19;15:9-26. doi: 10.2147/RRU.S350793. eCollection 2023.
2023
ASL Asti

Turco F; Di Prima L; Pisano C; Poletto S; De Filippis M; Crespi V; Farinea G; Cani M; Calabrese M; Saporita I; Di Stefano RF; Tucci M; Buttigliero C;

Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? in Cells / Cells. 2022 May 11;11(10):1614. doi: 10.3390/cells11101614.
2022
ASL Asti

Audisio M; Buttigliero C; Turco F; Delcuratolo MD; Pisano C; Parlagreco E; Di Stefano RF; Di Prima L; Crespi V; Farinea G; Cani M; Tucci M;

Darolutamide in Metastatic Prostate Cancer. in The New England journal of medicine / N Engl J Med. 2022 Jun 16;386(24):2344. doi: 10.1056/NEJMc2205310.
2022
ASL Asti

Turco F; Tucci M; Buttigliero C;

New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Jun;174:103682. doi: 10.1016/j.critrevonc.2022.103682. Epub 2022 Apr 11
2022
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Di Maio M; Scagliotti GV; Ortega C; Di Prima L; Audisio A; Turco F; Ungaro A; Di Stefano RF; Parlagreco E; Tucci M; Audisio M;

2022
ASL Asti
AOU San Luigi di Orbassano

Di Prima L; Di Stefano RF; Ungaro A; Audisio M; Parlagreco E; Delcuratolo MD; Buttigliero C; Audisio A; Turco F; Tucci M;

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. in Journal for immunotherapy of cancer / J Immunother Cancer. 2022 Jan;10(1):e003697. doi: 10.1136/jitc-2021-003697.
2022
ASL Asti

Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J;

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. in Journal of clinical pathology / J Clin Pathol. 2022 Jan;75(1):39-44. doi: 10.1136/jclinpath-2020-207089. Epub 2020 Nov 3.
2022
ASL Asti

Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; et alii...

2022
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Di Maio M; Scagliotti GV; Delcuratolo MD; Turco F; Di Prima L; Pisano C; Audisio A; Tucci M; Ungaro A;

2022
ASL Asti

Fiorica F; Buttigliero C; Grigolato D; Muraro M; Turco F; Munoz F; Tucci M;

Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study. in Minerva urology and nephrology / Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi: 10.23736/S2724-6051.22.04701-2. Epub 2022 Feb 11.
2022
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; DI Maio M; Tucci M; Scagliotti GV; Pisano C; Samuelly A; Turco F; Parente A; Bungaro M; DI Stefano RF; Angusti T;

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. in Cancer communications (London, England) / Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22.
2022
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Scagliotti GV; Buttigliero C; Di Maio M; Ortega C; Ungaro A; Audisio M; Pisano C; Audisio A; Di Stefano RF; Tucci M; Delcuratolo MD; Turco F;

2022
ASL Asti

Brunelli M; Martignoni G; Malpeli G; Volpe A; Cima L; Raspollini MR; Barbareschi M; Tafuri A; Masi G; Barzon L; Ammendola S; Villanova M; Cerruto MA; Milella M; Buti S; Bersanelli M; Fornarini G; Rebuzzi SE; Vellone VG; Gaggero G; Procopio G; Verzoni E; Bracarda S; Fanelli M; Sabbatini R; Passalacqua R; Perrucci B; Giganti MO; Donini M; et alii...

Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2021 Sep;24(3):812-825. doi: 10.1038/s41391-021-00336-1. Epub 2021 Fe
2021
ASL Asti
AO Ordine Mauriziano

Buttigliero C; Di Maio M; Gallicchio M; Scagliotti GV; Vignani F; Pisano C; Bungaro M; Samuelly A; Turco F; Tucci M; Di Stefano RF;

2021
ASL Asti
AO Cuneo
ASL Città di Torino
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Berruti A; Tucci M; Gennari A; Baier S; Bellissimo AR; Ciccone G; Montagnani F; Comandone A; Chiappino I; Dal Canton O; Masini C; Sacco C; Zamparini M; Sirotova Z; Fea E; Valcamonico F; Vanella P; Ortega C; Buttigliero C; Prati V; Bianchi S; Mosca A; Dalla Volta A; Amoroso D;

Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. in Cancers / Cancers (Basel). 2021 Nov 24;13(23):5896. doi: 10.3390/cancers13235896.
2021
ASL Asti
ASL Città di Torino

Tucci M; Comandone T; Vana F; Comandone A;

Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):807-815. doi: 10.2217/fon-2020-0391. Epub 2021 Jan 29.
2021
ASL Asti
AOU San Luigi di Orbassano

Salgarello M; Borsatti E; Pignata S; Zichi C; Filice A; Murabito A; Biasco E; Fanti S; Palermo A; Alongi P; Alongi F; Bortolus R; Facchini G; Baldari S; Tucci M; Pinto C; Costa RP; Sbrana A; Monari F; Caffo O; Frantellizzi V; Spada M; Cortesi E; Vincentis G;

Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. in Endocrine-related cancer / Endocr Relat Cancer. 2021 Jun 2;28(7):R207-R216. doi: 10.1530/ERC-20-0457.
2021
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Scagliotti GV; Di Maio M; Pisano C; Audisio M; Bungaro M; Tucci M; Di Stefano RF; Samuelly A; Turco F;

Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without (223)Ra. in Cancer biotherapy & radiopharmaceuticals / Cancer Biother Radiopharm. 2021 Jun;36(5):391-396. doi: 10.1089/cbr.2020.4442. Epub 2021 Mar 25.
2021
ASL Asti
AOU San Luigi di Orbassano

Spada M; Salgarello M; Borsatti E; Pignata S; Zichi C; Masini C; Morabito A; Fanti S; Sbrana A; Donner D; Alongi P; Alongi F; Bortolus R; Facchini G; Tucci M; Baldari S; Pinto C; Costa RP; Galli L; Monari F; Caffo O; Frantellizzi V; De Giorgi U; Lo Re G; Cortesi E; De Vincentis G;

Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2021 Jan;157:103185. doi: 10.1016/j.critrevonc.2020.103185. Epub 2020 Nov 27
2021
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Pisano C; Tucci M; Di Stefano RF; Turco F; Scagliotti GV; Di Maio M;

Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):870-872. doi: 10.23736/S2724-6051.21.04817-5.
2021
ASL Asti
AOU San Luigi di Orbassano

Buttigliero C; Tucci M; Turco F;

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi: 10.23736/S2724-6051.21.04186-2. Epub 2021 Mar 29.
2021
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; DI Maio M; Scagliotti GV; Tarenghi F; Bungaro M; Vignani F; Samuelly A; DI Stefano RF; Turco F; Tucci M; Pisano C;

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report. in Tumori / Tumori. 2021 Dec;107(6):NP149-NP154. doi: 10.1177/03008916211059230. Epub 2021 Nov 11.
2021
ASL Asti
AOU San Luigi di Orbassano

Scagliotti GV; Bollito E; Bungaro M; Samuelly A; Tucci M; Di Stefano RF; Turco F; Buttigliero C;

2021
ASL Asti
AO Ordine Mauriziano

Beretta GD; Cinieri S; Tucci M; Perrone F; La Verde N; Del Mastro L; Giuffrida D; De Giorgi U; Chiari R; Russo A; Di Maio M; Silvestris N;

2020
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Di Maio M; Tucci M; Gamba T; Necchi A; Buttigliero C; Vignani F; Marandino L;

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18.
2020
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Procopio G; Mucciarini C; Mosca A; Massari F; Masini C; Fratino L; Ermacora P; Fornarini G; Donini M; Ceresoli GL; Buti S; Bortolus R; Berruti A; Baldessari C; Zagonel V; Caffo O; Buttigliero C; Zucali P; Verri E;

The prognostic value of pain in castration-sensitive prostate cancer. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2020 Dec;23(4):654-660. doi: 10.1038/s41391-020-0255-x. Epub 2020 Jul
2020
ASL Asti

Iacovelli R; Ciccarese C; Caffo O; De Giorgi U; Tucci M; Mosillo C; Bimbatti D; Pierantoni F; Maines F; Casadei C; Buttigliero C; Milella M; Tortora G;

Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2020 Aug;152:102994. doi: 10.1016/j.critrevonc.2020.102994. Epub 2020 May 24
2020
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tucci M; Di Maio M; Scagliotti GV; Vignani F; Tabbò F; Turco F; Di Stefano RF; Buttigliero C; Pisano C; Leone G;

Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. in Cancer drug resistance (Alhambra, Calif.) / Cancer Drug Resist. 2020 Sep 12;3(4):726-741. doi: 10.20517/cdr.2020.42. eCollection 2020.
2020
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Buttigliero C; Bungaro M;

2019
ASL Asti
AOU San Luigi di Orbassano

Sigala S; Buttigliero C; Vittorio Scagliotti G; Bedussi F; Dalla Volta A; Pia A; Ferrari L; Tucci M; Roca E; Berruti A;